ClinicaliQ Trial Snapshot
- Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Active Not Recruiting • Phase III • Oncology • NCT05089734.
- New drug sacituzumab govitecan compared to standard chemotherapy docetaxel for advanced lung cancer.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC). Conditions: Non-Small Cell Lung Cancer Interventions: Sacituzumab Govitecan-hziy (SG), Docetaxel Lead Sponsor: Gilead Sciences Planned Enrollment: 603 participants